Evaluation of ovarian reserve before and after chemotherapy.
Adolescent
Adult
Anti-Mullerian Hormone
/ analysis
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Bleomycin
/ adverse effects
Breast Neoplasms
/ drug therapy
Cyclophosphamide
/ adverse effects
Dacarbazine
/ adverse effects
Docetaxel
/ adverse effects
Doxorubicin
/ adverse effects
Epirubicin
/ adverse effects
Etoposide
/ adverse effects
Female
Fertility Preservation
Fluorouracil
/ adverse effects
Hodgkin Disease
/ drug therapy
Humans
Longitudinal Studies
Luminescent Measurements
/ methods
Ovarian Reserve
/ drug effects
Prednisone
/ adverse effects
Procarbazine
/ adverse effects
Vinblastine
/ adverse effects
Vincristine
/ adverse effects
Young Adult
Anti-mullerian hormone
Chemotherapy
Fertility preservation
Ovarian reserve
Journal
Journal of gynecology obstetrics and human reproduction
ISSN: 2468-7847
Titre abrégé: J Gynecol Obstet Hum Reprod
Pays: France
ID NLM: 101701588
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
16
08
2020
revised:
20
11
2020
accepted:
03
12
2020
pubmed:
12
12
2020
medline:
6
11
2021
entrez:
11
12
2020
Statut:
ppublish
Résumé
Progress in oncology has improved patient survival. However, cancer chemotherapy can be gonadotoxic and affect their fertility. Recourse to fertility preservation before starting these treatments is therefore necessary in order to allow a better life quality after survival. The aim of this work was to study the impact of chemotherapy on ovarian reserve by AMH measurement. This is a descriptive and longitudinal study from 2015 to 2018 carried out at Aziza Othmana hospital ART center in Tunis on patient aged less than 41 years who were candidates for fertility preservation. Patients included had AMH measurement prior to cancer treatment. We called them back to follow up the AMH level after chemotherapy. The AMH assay was performed by electrochemilumiescence technique. At the end, only 66 patients met the inclusion criteria. The most frequent pathologies were Hodgkin's lymphoma and breast cancer. The mean age of patients was 26.7 ± 6.8. The most used chemotherapy protocols were BEACOPP, ABVD or the combination of both in lymphoma and FEC + TXT for breast cancer treatment. A significant difference between AMH before and after chemotherapy was found for BEACOPP and FEC + TXT protocols (p < 10 3). The patient's age was correlated with the AMH decrease after chemotherapy (r = 0.577, p < 10 3). Our results showed that the high risk gonadotoxicity protocols were BEACOPP for lymphoma treatment and FEC + TXT for breast cancer treatment. However, studies with a larger sample and more time extended monitoring are necessary for a better gonadotoxicity understanding of the cancer treatments available today.
Sections du résumé
BACKGROUND
BACKGROUND
Progress in oncology has improved patient survival. However, cancer chemotherapy can be gonadotoxic and affect their fertility. Recourse to fertility preservation before starting these treatments is therefore necessary in order to allow a better life quality after survival. The aim of this work was to study the impact of chemotherapy on ovarian reserve by AMH measurement.
METHODS
METHODS
This is a descriptive and longitudinal study from 2015 to 2018 carried out at Aziza Othmana hospital ART center in Tunis on patient aged less than 41 years who were candidates for fertility preservation. Patients included had AMH measurement prior to cancer treatment. We called them back to follow up the AMH level after chemotherapy. The AMH assay was performed by electrochemilumiescence technique. At the end, only 66 patients met the inclusion criteria.
RESULTS
RESULTS
The most frequent pathologies were Hodgkin's lymphoma and breast cancer. The mean age of patients was 26.7 ± 6.8. The most used chemotherapy protocols were BEACOPP, ABVD or the combination of both in lymphoma and FEC + TXT for breast cancer treatment. A significant difference between AMH before and after chemotherapy was found for BEACOPP and FEC + TXT protocols (p < 10 3). The patient's age was correlated with the AMH decrease after chemotherapy (r = 0.577, p < 10 3).
CONCLUSION
CONCLUSIONS
Our results showed that the high risk gonadotoxicity protocols were BEACOPP for lymphoma treatment and FEC + TXT for breast cancer treatment. However, studies with a larger sample and more time extended monitoring are necessary for a better gonadotoxicity understanding of the cancer treatments available today.
Identifiants
pubmed: 33307239
pii: S2468-7847(20)30411-6
doi: 10.1016/j.jogoh.2020.102035
pii:
doi:
Substances chimiques
Bleomycin
11056-06-7
Docetaxel
15H5577CQD
Procarbazine
35S93Y190K
Epirubicin
3Z8479ZZ5X
Vincristine
5J49Q6B70F
Vinblastine
5V9KLZ54CY
Etoposide
6PLQ3CP4P3
Dacarbazine
7GR28W0FJI
Doxorubicin
80168379AG
Anti-Mullerian Hormone
80497-65-0
Cyclophosphamide
8N3DW7272P
Fluorouracil
U3P01618RT
Prednisone
VB0R961HZT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
102035Informations de copyright
Copyright © 2020 Elsevier Masson SAS. All rights reserved.
Déclaration de conflit d'intérêts
Declarations of Competing Interest None.